All sponsors

Biohaven Therapeutics Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-36
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO40%

Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Biohaven Therapeutics Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Taldefgrobep Alfa
NCT07281495
P2Active, not recruitingObesity; Overweight1502026-09
RISE 3
NCT06309966
P2/3Active, not recruitingFocal Epilepsy3902026-10 (+14 mo)
BHV-7000
NCT06443463
P2Enrolling by invitationFocal Epilepsy6602026-12
RISE 2
NCT06132893
P2/3Active, not recruitingFocal Epilepsy3902026-12 (+16 mo)
BHV-8000 10mg
NCT06976268
P2/3RecruitingParkinson Disease5502027-08
BHV-1300
NCT07661056
P3RecruitingGraves Disease3002028-01
BHV-1510
NCT06384807
P1/2RecruitingSolid Tumor5002028-02
BHV-1400
NCT07642050
P3Not yet recruitingIgA Nephropathy4202028-09
BHV-1300
NCT07901244
P2/3Not yet recruitingGraves' Disease3562028-12